A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0034 in Adult Healthy Subjects
Latest Information Update: 16 Sep 2022
At a glance
- Drugs HB 0034 (Primary)
- Indications Pustular psoriasis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Adverse reactions; First in man
- Sponsors Huaota Biopharmaceuticals
- 12 Sep 2022 Status changed from recruiting to completed.
- 22 Aug 2022 Planned primary completion date changed from 1 Dec 2022 to 10 Sep 2022.
- 09 Nov 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2021 to 3 Dec 2021.